Patent · US Active

Combination immunotherapy for the treatment of cancer

US10167337B2 · kind B2 · utility

3Cited by

31References

19Claims

0Family size

Assignees

Memorial Sloan Kettering Cancer Center · US
The Board of Regents of the University of Texas System · US

Inventors

James Allison · New York, US
Padmanee Sharma · Bellaire, US
Sergio Quezada · London, GB
Tihui Fu · Houston, US

Key dates

Filing date	May 4, 2018
Grant date	Jan 1, 2019
Priority date	—
Expiry date	May 4, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.